The Done Global Telehealth Prescription Scam: A $100 Million Controlled Substance Cash-Out Scheme Disguised as AI-Driven Care

Who Gets Targeted

Victims fall into two main categories: First, ADHD patients desperate for treatment, mostly young professionals and students aged 20 to 40 who struggled to book in-person psychiatric appointments during the pandemic. They were lured by the platform's promises of 'same-day diagnosis and rapid prescription' and mistakenly believed they were receiving legitimate medical care. Second, insurance companies and government healthcare systems, which paid over $100 million for prescriptions that did not meet clinical criteria. Patients' psychological vulnerabilities—anxiety and the stigma surrounding mental health—led them to prefer anonymous online channels. The platform's subscription model created a cycle of dependency, and many only realized they were part of a drug cash-out scheme when the prosecution began.

骗局怎么运作

• Step 1: Lead generation through targeted advertising. The platform ran massive social media campaigns for 'ADHD self-tests' and 'same-day diagnosis,' targeting young people unable to book appointments with local psychiatrists, using slogans like 'skip the wait, get diagnosed online in three minutes' to exploit medical anxiety.
• Step 2: Creating a superficial AI-driven consultation process. After filling out a questionnaire, patients were assigned to a nurse practitioner or doctor for a very brief video consultation. The time was artificially compressed, and clinical assessments were merely a formality; almost everyone was diagnosed with ADHD to provide a veneer of compliance for prescribing.
• Step 3: Mass issuance of Adderall and other federally controlled stimulants. Prosecutors alleged the company instructed doctors to refuse alternative treatments and only prescribe controlled substances, pressuring those who resisted and turning medical decision-making into an assembly-line operation.
• Step 4: Locking in repeat business with subscriptions. Patients were required to pay monthly fees to continue receiving refills. Prescription eligibility was tied to subscription renewals, creating stable recurring revenue that appeared as high-growth health tech on financial reports.
• Step 5: Fraudulent billing to insurance companies and federal programs. Prosecutors alleged the company used false diagnoses and fraudulent billing to extract insurance payments, totaling approximately $100 million, while restricting communication with pharmacies and concealing actual medical records to hide the scale of prescriptions.
• Step 6: Attempting to cover up after being exposed. According to prosecutors, the founder destroyed evidence, transferred assets, and discussed fleeing the country during the investigation. She was eventually arrested in Los Angeles in June 2024, and a federal jury found her guilty in November 2024.

红旗信号（看到这些快跑）

• 🚩 Telehealth platforms promising 'prescriptions for controlled substances without an in-person visit,' especially for highly regulated items like ADHD stimulants, opioids, or weight-loss injections.
• 🚩 Abnormally short consultation times where a diagnosis and prescription are issued within minutes, with no verification of past medical history or follow-up management—resembling an assembly line.
• 🚩 Mandatory bundling of prescription eligibility with monthly subscriptions; stopping the subscription leads to a cutoff of medication, prioritizing user retention over clinical efficacy.
• 🚩 Companies recruiting nurse practitioners and doctors with high salaries and setting prescription quotas, while pressuring or replacing medical staff who refuse to prescribe controlled substances.
• 🚩 Founding teams transferring assets, destroying chat logs, or planning to leave the country when regulations tighten—a classic high-risk signal before a case breaks.
• 🚩 Using 'AI-assisted diagnosis' and other tech buzzwords to package what is essentially a prescription sales business, where financial reports are severely disconnected from clinical compliance.

真实案例

• In June 2024, the U.S. Department of Justice announced the arrest of Done Global founder and CEO Ruthia He and its clinical president, charging them with a $100 million healthcare fraud scheme involving the distribution of over 40 million pills of Adderall and other controlled substances, marking the largest telehealth controlled-substance case in U.S. history at the time.
• In November 2024, a federal jury in the Northern District of California found He guilty of healthcare fraud, conspiracy, and obstruction of justice. Evidence showed she instructed doctors to prescribe only stimulants, restricted pharmacy communication, and destroyed evidence during the investigation.
• In July 2026, according to public reports and Chinese media, He appeared in a San Francisco federal court in a grey prison uniform. The sentencing and subsequent proceedings were widely covered by Silicon Valley and Chinese venture capital media, viewed as a landmark reckoning for the 'wild west' growth of telehealth during the pandemic.
• The U.S. Drug Enforcement Administration (DEA) and the Department of Justice noted that many patients who did not meet clinical criteria received controlled prescriptions, with some drugs entering non-medical channels, highlighting the direct harm of fraudulent care to public health.
• In November 2025, a U.S. federal jury in San Francisco found Done Global founder and former CEO Ruthia He and clinical president David Brody guilty of multiple felonies, including distribution of controlled substances and conspiracy to commit wire fraud. The company distributed over 40 million pills of Adderall and other controlled substances during the pandemic. (Source: https://www.sohu.com/a/992213174_121948416)
• In November 2024, the U.S. Department of Justice announced that a San Francisco federal jury had convicted Done founder and CEO Ruthia He and clinical president David Brody of years of illegal online distribution of Adderall. The two conspired to profit through false and fraudulent claims, involving the distribution of over 40 million controlled pills. (Source: https://www.tmtpost.com/7794941.html)

Official Stance

• On June 13, 2024, the U.S. Department of Justice issued a press release announcing the indictment of Done Global's founder and clinical president for orchestrating a $100 million telehealth fraud and illegal distribution scheme.
• In June 2024, the DEA issued a statement regarding the case, warning that telehealth platforms were being used as channels for mass-prescribing controlled stimulants and pushing for tighter regulations on remote prescriptions.
• In November 2024, the U.S. Attorney's Office for the Northern District of California announced the jury's guilty verdict and disclosed specific details regarding the obstruction of justice and destruction of evidence.
• In 2026, the U.S. judicial system continued proceedings for the case, with federal courts releasing numerous documents regarding sentencing and related civil litigation, serving as a landmark precedent for telehealth compliance.

How to Protect Yourself

• ✅ When choosing a telehealth platform, verify if it holds state-level practice licenses and discloses physician credentials. Avoid any platform that guarantees a prescription.
• ✅ Consultations involving controlled substances should include a comprehensive clinical assessment, including medical history, verification of past medications, and regular follow-ups. Do not accept services that prescribe after only a few minutes of video.
• ✅ When conducting due diligence on digital health companies, investors should look past subscription growth curves to verify prescription compliance rates, physician incentive structures, and the authenticity of insurance claims.
• ✅ Medical professionals pressured by companies to meet prescription quotas for controlled substances should report the matter to state medical boards or federal health authorities and retain written instructions as evidence.
• ✅ Stay updated on the latest DEA and DOJ rules regarding remote prescriptions. Business models involving controlled substances are under high-pressure scrutiny in most jurisdictions.